Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective comparison with previously known prognostic models

Oncology

Volumn 80, Issue 3-4, 2011, Pages 167-174

  Baek, Kyung Kee ^a   Kim, Jung Hoon ^a   Uhm, Ji Eun ^a   Park, Se Hoon ^a   Lee, Jeeyun ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Advanced hepatocellular carcinoma; Prognostic factors; Sorafenib

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER OF THE LIVER ITALIAN PROGRAM SCORING SYSTEM; CANCER SURVIVAL; CHILD PUGH CLASSIFICATION; CLINICAL FEATURE; DRUG DOSE REDUCTION; FAILURE FREE SURVIVAL; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OKUDA STAGING; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PYRIDINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; YOUNG ADULT;

EID: 79959421984     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000327591     Document Type: Article

References (16)

1. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korea Central Cancer Registry Program 2000. Cancer Res Treat 2002; 34: 77-83.
2. Simonetti RG, Liberati A, Angiolini C, Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136. (Pubitemid 27112878)
3. Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40: 1474-1484. (Pubitemid 38757734)
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
5. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor Bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972. (Pubitemid 46202316)
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
8. Nzeako UC, Goodman ZD, Ishak KG: Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65-75.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520. (Pubitemid 24166476)
10. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928. (Pubitemid 15228292)
11. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.
12. Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S, Yamaoka Y: A modified Japan integrated stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41: 884-892. (Pubitemid 44594230)
13. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48(suppl 1):S20-S37.
16. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.